Investors

Media

Welcome to the new Regeneron Newsroom. This newsroom is designed to provide members of the media with easy access to up-to-date information about the Company.

For an e-mail response to questions about Regeneron, please contact us at media@regeneron.com.



Upcoming Events

Aug 5, 2014
8:30 AM ET
Webcast Regeneron Pharmaceuticals Q2 2014 Earnings Conference Call


View all releases Recent Press Releases

Jul 30, 2014 Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
Jul 30, 2014 Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia
Jul 29, 2014 EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME)
Jul 18, 2014 Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014
Jul 18, 2014 Two-Year Results From Phase 3 VIVID-DME Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision
Jul 9, 2014 Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
Jun 27, 2014 EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union
Jun 12, 2014 Sanofi and Regeneron Announce New, Detailed Data from Positive Sarilumab Phase 3 Rheumatoid Arthritis Trial at EULAR
Jun 11, 2014 EYLEA® (aflibercept) Injection Submitted for EU Marketing Authorization for the Treatment of Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
Jun 2, 2014 Regeneron Announces Winners of the 2014 Regeneron Prize for Creative Innovation


Close
Form content here please :)